Abivax (Euronext Paris: ABVX) announced that trading of its ordinary shares on Euronext Paris will resume on July 1, 2026 at 3:30 p.m. CEST.
Trading was halted at the Company’s request from 9:00 a.m. CEST in connection with allocation confirmation and pricing of its US ADS public offering.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – ABVX
-0.53%
49 alerts
-0.53%Session close to close
+5.6%Peak in 31 hr 29 min
$11.62BMarket Cap
0.8xRel. Volume
In the Jul 1 session, ABVX declined 0.53%, reflecting a mild negative market reaction.
Argus tracked a peak move of +5.6% during that session.
Our momentum scanner triggered 49 alerts that day, indicating elevated trading interest and price volatility.
This announcement confirms resumption of Euronext Paris trading after an ADS public offering process...
Analysis
This announcement confirms resumption of Euronext Paris trading after an ADS public offering process, tying trading mechanics to ongoing U.S. capital raising. Investors should monitor offering size, pricing details and any follow‑on financings as potential overhangs.
Key Figures
Trading halt time:9:00 a.m. CESTTrading resumption time:3:30 p.m. CESTAnnouncement time:2:50 p.m. CEST+2 more
5 metrics
Trading halt time9:00 a.m. CESTStart of trading halt on July 1, 2026 for ADS offering allocations
Trading resumption time3:30 p.m. CESTResumption of ordinary share trading on Euronext Paris
Announcement time2:50 p.m. CESTTime of press release announcing trading resumption
Nominal value per share€0.01 per shareOrdinary share nominal value referenced in ADS public offering
ADS-to-share ratio1 ADS = 1 ordinary shareEach American Depositary Share represents one ordinary share
Royalty certificate repurchase and $45M ADS offering improving capital structure and liquidity.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
ABVX usually trades in line with the tone of major clinical and financing news, with one notable negative divergence after strong Phase 3 data.
Key Terms
american depositary shares, public offering, regulated market, nominal value
4 terms
american depositary sharesfinancial
"previously announced public offering by the Company of its American Depositary Shares, each representing one ordinary share"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
public offeringfinancial
"in the context of the previously announced public offering by the Company of its American Depositary Shares"
A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.
regulated marketregulatory
"trading resumption of its ordinary shares on the regulated market of Euronext Paris"
A regulated market is an organized trading venue overseen by government or independent authorities that enforces rules on who can list, what information must be published, and how trades are executed. Think of it like a store that must pass safety inspections and display clear labels: the oversight promotes honesty, regular reporting, and fair access, which helps investors compare options, find buyers and sellers, and reduces the risk of fraud or hidden problems.
nominal valuefinancial
"each representing one ordinary share, €0.01 nominal value per share, of the Company"
Nominal value is the stated or face amount assigned to a financial instrument — for shares it’s the par value printed on the stock certificate, and for money or returns it can mean the number not adjusted for inflation. Think of it like a price tag on an item versus its buying power: the tag tells you the label, but not how much you can actually buy. Investors care because nominal values affect accounting, legal capital, dividend calculations and comparisons over time when inflation may distort real worth.
Abivax announces trading resumption of its ordinary shares on Euronext Paris
PARIS, France, July 1, 2026 – 02:50 p.m. CEST –Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. CEST.
Trading of the ordinary shares of the Company was halted at the request of the Company on July 1, 2026 from 9:00 a.m. CEST in the context of the previously announced public offering by the Company of its American Depositary Shares, each representing one ordinary share, €0.01 nominal value per share, of the Company, in the United States (the “Offering”), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Offering.
***
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
When did Abivax (ABVX) shares resume trading on Euronext Paris on July 1, 2026?
Abivax shares resumed trading on Euronext Paris at 3:30 p.m. CEST on July 1, 2026. According to Abivax, this followed a temporary halt earlier that day related to its American Depositary Shares public offering in the United States.
Why was Abivax (ABVX) trading halted on Euronext Paris on July 1, 2026?
Trading in Abivax ordinary shares was halted at the Company’s request from 9:00 a.m. CEST on July 1, 2026. According to Abivax, the pause related to confirming investor allocations and announcing pricing for its US American Depositary Shares public offering.
How is the Abivax (ABVX) US ADS public offering linked to the Euronext Paris trading halt?
The Euronext Paris trading halt was requested in the context of Abivax’s US American Depositary Shares (ADS) public offering. According to Abivax, the pause allowed time to confirm allocations to investors and communicate final pricing for the ADS Offering.
What securities are involved in the Abivax (ABVX) US public offering mentioned on July 1, 2026?
The US public offering involves American Depositary Shares (ADS), each representing one Abivax ordinary share with €0.01 nominal value. According to Abivax, the trading halt and resumption on Euronext Paris were timed around allocation confirmation and pricing of this ADS Offering.
Does the Abivax (ABVX) trading resumption affect its ordinary shares or only ADS on July 1, 2026?
The trading resumption announced for July 1, 2026 concerns Abivax ordinary shares on Euronext Paris. According to Abivax, trading was briefly halted on this market in connection with its separate US American Depositary Shares public offering and related allocation and pricing steps.
